JPWO2020218518A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020218518A5
JPWO2020218518A5 JP2021516266A JP2021516266A JPWO2020218518A5 JP WO2020218518 A5 JPWO2020218518 A5 JP WO2020218518A5 JP 2021516266 A JP2021516266 A JP 2021516266A JP 2021516266 A JP2021516266 A JP 2021516266A JP WO2020218518 A5 JPWO2020218518 A5 JP WO2020218518A5
Authority
JP
Japan
Prior art keywords
particle component
pharmaceutical preparation
nuclear particle
nuclear
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021516266A
Other languages
English (en)
Japanese (ja)
Other versions
JP7183403B2 (ja
JPWO2020218518A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/017711 external-priority patent/WO2020218518A1/ja
Publication of JPWO2020218518A1 publication Critical patent/JPWO2020218518A1/ja
Publication of JPWO2020218518A5 publication Critical patent/JPWO2020218518A5/ja
Application granted granted Critical
Publication of JP7183403B2 publication Critical patent/JP7183403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021516266A 2019-04-25 2020-04-24 医薬製剤およびその製造方法 Active JP7183403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019084695 2019-04-25
JP2019084695 2019-04-25
PCT/JP2020/017711 WO2020218518A1 (ja) 2019-04-25 2020-04-24 医薬製剤およびその製造方法

Publications (3)

Publication Number Publication Date
JPWO2020218518A1 JPWO2020218518A1 (https=) 2020-10-29
JPWO2020218518A5 true JPWO2020218518A5 (https=) 2022-03-22
JP7183403B2 JP7183403B2 (ja) 2022-12-05

Family

ID=72942137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516266A Active JP7183403B2 (ja) 2019-04-25 2020-04-24 医薬製剤およびその製造方法

Country Status (11)

Country Link
US (1) US20220211688A1 (https=)
EP (1) EP3960240B1 (https=)
JP (1) JP7183403B2 (https=)
KR (1) KR102789488B1 (https=)
CN (1) CN114126590B (https=)
BR (1) BR112021021232A2 (https=)
ES (1) ES2977747T3 (https=)
PL (1) PL3960240T3 (https=)
TW (1) TWI829920B (https=)
WO (1) WO2020218518A1 (https=)
ZA (1) ZA202108670B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI890738B (zh) * 2020-10-28 2025-07-21 日商基諾製藥股份有限公司 用於預防或治療病毒性陰道周邊部疾病的藥物組成物
CN119497616A (zh) * 2022-05-02 2025-02-21 株式会社基诺制药 含有苯胺衍生物的皮肤用外用剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CA2427991C (en) * 2000-11-06 2008-01-22 Asahi Kasei Kabushiki Kaisha Cellulose particles for pharmaceuticals
JP2004339162A (ja) * 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
JP2007517062A (ja) 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
JP2006016329A (ja) * 2004-06-30 2006-01-19 Lion Corp 粒状医薬品
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗dnaウイルス作用を有するアニリン誘導体
MY164765A (en) * 2007-10-10 2018-01-30 Avantor Performance Mat Llc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100151034A1 (en) * 2008-09-30 2010-06-17 Astellas Pharma Inc. Granular pharmaceutical composition of atorvastatin for oral administration
JP2010189337A (ja) * 2009-02-19 2010-09-02 Asahi Breweries Ltd 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法
JP6138635B2 (ja) 2013-08-30 2017-05-31 旭化成株式会社 セルロース系核粒子及びその製造方法
CA2944727A1 (en) * 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
JP2019084695A (ja) 2017-11-02 2019-06-06 キヤノンファインテックニスカ株式会社 記録装置

Similar Documents

Publication Publication Date Title
JP3009713B2 (ja) 二重被覆顆粒
JP2015205922A5 (https=)
JP2011063611A (ja) シロスタゾール製剤
JP4748839B2 (ja) シロスタゾール製剤
WO2014030204A1 (ja) 薬物含有中空粒子
JP2012051810A (ja) 口腔内崩壊錠およびその製造法
CN101686944A (zh) 熊去氧胆酸的高剂量组合物
JPWO2020218518A5 (https=)
JP2017122056A (ja) 医薬含有造粒物の製造方法
JP3491887B2 (ja) 糖アルコール造粒物集合体の製法
CN1882321A (zh) 包含盐酸文拉法辛的小丸
US20100221335A1 (en) Sustained-release preparation and method for producing the same
Jadhav et al. Pelletization by extrusion spheronization technique: an excipient review
JP6308938B2 (ja) 粒状物を製造する方法
TWI829920B (zh) 醫藥製劑及其之製造方法
JP2013023463A (ja) 生理活性物質含有粒子の製造方法
CN102824316A (zh) 埃索美拉唑含药微丸及其制备方法
JP2013043834A (ja) 溶出改善固形製剤
JPWO2020218517A5 (https=)
JP4493769B2 (ja) 球形顆粒
JP2019156723A (ja) 圧縮成形性に優れた賦形剤を用いる、浸透膨潤型口腔内崩壊錠
EP3344242B1 (en) Stable multiparticuate pharamaceutical composition of rosuvastatin
CN106031715A (zh) 一种盐酸多西环素缓释制剂及其制备方法
Kumaravelrajan et al. Application of Factorial Design in the Premixing Operation of Diltiazem Timed-Release Pellets.
TH2101006685A (th) ยาเตรียมและวิธีการผลิตยาเตรียมดังกล่าว